Kodiak Sciences Inc. (KOD) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Palo Alto, CA, 美国. 现任CEO为 Victor Perlroth.
KOD 拥有 IPO日期为 2018-10-04, 109 名全职员工, 在 NASDAQ Global Market, 市值为 $2.39B.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
